These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 32796402)
1. A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways. Matossian MD; Burks HE; Elliott S; Hoang VT; Zuercher WJ; Wells C; Drewry DH; Kapadia N; Chang T; Yan T; Windsor GO; Nguyen K; Fang F; Nephew KP; Buechlein A; Rusch DB; Sabol RA; Ucar DA; Zabaleta J; Miele L; Bunnell BA; Collins-Burow BM; Burow ME Anticancer Drugs; 2020 Sep; 31(8):759-775. PubMed ID: 32796402 [TBL] [Abstract][Full Text] [Related]
2. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer. Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991 [TBL] [Abstract][Full Text] [Related]
3. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer. Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152 [TBL] [Abstract][Full Text] [Related]
4. Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes. Matossian MD; Elliott S; Hoang VT; Burks HE; Phamduy TB; Chrisey DB; Zuercher WJ; Drewry DH; Wells C; Collins-Burow B; Burow ME PLoS One; 2017; 12(8):e0177802. PubMed ID: 28771473 [TBL] [Abstract][Full Text] [Related]
5. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. Gagliardi M; Pitner MK; Park J; Xie X; Saso H; Larson RA; Sammons RM; Chen H; Wei C; Masuda H; Chauhan G; Kondo K; Tripathy D; Ueno NT; Dalby KN; Debeb BG; Bartholomeusz C Sci Rep; 2020 May; 10(1):8537. PubMed ID: 32444778 [TBL] [Abstract][Full Text] [Related]
6. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463 [TBL] [Abstract][Full Text] [Related]
7. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. Bartholomeusz C; Xie X; Pitner MK; Kondo K; Dadbin A; Lee J; Saso H; Smith PD; Dalby KN; Ueno NT Mol Cancer Ther; 2015 Dec; 14(12):2773-81. PubMed ID: 26384399 [TBL] [Abstract][Full Text] [Related]
8. Inhibitory Impact Of Cinobufagin In Triple-Negative Breast Cancer Metastasis: Involvements Of Macrophage Reprogramming Through Upregulated MME and Inactivated FAK/STAT3 Signaling. Zhu Z; Wang H; Qian X; Xue M; Sun A; Yin Y; Tang J; Zhang J Clin Breast Cancer; 2024 Jun; 24(4):e244-e257.e1. PubMed ID: 38378361 [TBL] [Abstract][Full Text] [Related]
9. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691 [TBL] [Abstract][Full Text] [Related]
10. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer. Ring A; Kaur P; Lang JE BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919 [TBL] [Abstract][Full Text] [Related]
11. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer. Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818 [TBL] [Abstract][Full Text] [Related]
12. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232 [TBL] [Abstract][Full Text] [Related]
13. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells. Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364 [TBL] [Abstract][Full Text] [Related]
14. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer. Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988 [TBL] [Abstract][Full Text] [Related]
15. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin. Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215 [TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer. Zhao R; Fu L; Yuan Z; Liu Y; Zhang K; Chen Y; Wang L; Sun D; Chen L; Liu B; Zhang L Eur J Med Chem; 2021 Jan; 210():113088. PubMed ID: 33316691 [TBL] [Abstract][Full Text] [Related]
17. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs. Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698 [TBL] [Abstract][Full Text] [Related]
18. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer. Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin. Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845 [TBL] [Abstract][Full Text] [Related]
20. Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of β-catenin expression. Lin D; Kuang G; Wan J; Zhang X; Li H; Gong X; Li H Oncol Rep; 2017 Feb; 37(2):895-902. PubMed ID: 27959422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]